Neumora’s schizophrenia drug hit with clinical hold

Shares of Neumora Therapeutics fell Monday after the company disclosed a small clinical trial testing one of its experimental medicines for schizophrenia has been halted by the Food and Drug Administration.

According to Neumora, the hold comes on the heels of new data from animal testing that found rabbits convulsed after receiving the medicine, which is codenamed NMRA-266. The company noted that, in the now-paused Phase 1 trial, researchers have dosed around 30 people and seen no evidence of convulsions.

Neumora said it’s working with the FDA to resolve the hold. But with discussions ongoing, the company warned that any prior guidance regarding NMRA-266 is “no longer applicable.” Neumora plans to provide an update on on the program “when available.”

“We are disappointed with the unanticipated safety findings in rabbits and are discussing next steps with the FDA,” said CEO Henry Gosebruch in a statement. “In parallel, we’re…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks